Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Verve Therapeutics Inc
(NQ:
VERV
)
5.790
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verve Therapeutics Inc
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
March 02, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Better Buy: Beam Therapeutics or Intellia Therapeutics?
February 22, 2023
The two clinical-stage gene-editing companies have good long-term prospects.
Via
The Motley Fool
3 Deeply Undervalued Stocks That Could Double Your Money
February 15, 2023
These cutting-edge biotech stocks hold tremendous upside potential.
Via
The Motley Fool
Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia
February 14, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Why Verve Therapeutics' Stock Dropped 26.33% on Monday
November 07, 2022
A trial for the company's lead therapy was put on hold.
Via
The Motley Fool
Being Cautious On Regulatory/Commercial Path, This Analyst Initiates Coverage On Verve Therapeutics
February 01, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
February 01, 2023
Via
Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
Via
InvestorPlace
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'
January 04, 2023
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams.
Via
Benzinga
Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Verve Therapeutics
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
December 23, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
December 22, 2022
Crispr and Vertex are working toward the first submissions for a CRISPR-based product.
Via
Investor's Business Daily
Analyst Beefs Up Beam Therapeutics Price Target, Says 'Reward Is Now Skewed To Upside'
December 20, 2022
Via
Benzinga
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session
December 15, 2022
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
Via
Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
December 15, 2022
The growth-focused money manager is making moves.
Via
The Motley Fool
Cathie Wood Adds $7M Of This Clinical-Stage Biotech, Trims Stake In CVS-Target Signify Health
December 07, 2022
Cathie Wood-led ARK Investment Management bought over 330,000 shares of clinical-stage biotechnology company Verve Therapeutics Inc (NASDAQ: VERV) at an estimated valuation of over $6.9 million, based...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
December 15, 2022
Via
Benzinga
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
December 05, 2022
Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share.
Via
Benzinga
Gold Down 1%; China Pharma Shares Spike Higher
December 05, 2022
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 200 points on Monday.
Via
Benzinga
VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday
December 05, 2022
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
US Stocks Start Week On Lower Note; Dow Tumbles 250 Points
December 05, 2022
U.S. stocks traded lower this morning, with the Dow Jones falling around 250 points on Monday.
Via
Benzinga
Verve Therapeutics Stock Skids On The FDA's Long List Of Gene-Editing Concerns
December 05, 2022
The company has a long list of issues to address to satisfy the FDA's worries.
Via
Investor's Business Daily
Looking Into Verve Therapeutics's Recent Short Interest
November 23, 2022
Verve Therapeutics's (NASDAQ:VERV) short percent of float has fallen 10.98% since its last report. The company recently reported that it has 10.05 million shares sold short, which is 29.91% of all...
Via
Benzinga
Verve Therapeutics to Participate in Upcoming Investor Conferences
November 11, 2022
From
Verve Therapeutics
Via
GlobeNewswire
Dow Surges 400 Points; Crude Oil Down 1%
November 07, 2022
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 400 points on Monday.
Via
Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
November 08, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
November 07, 2022
Gainers
Via
Benzinga
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
November 07, 2022
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870.
Via
Benzinga
Looking Into Verve Therapeutics's Recent Short Interest
November 07, 2022
Verve Therapeutics's (NASDAQ:VERV) short percent of float has fallen 11.53% since its last report. The company recently reported that it has 10.73 million shares sold short, which is 33.6% of all...
Via
Benzinga
Dow Jumps Over 200 Points; Verve Therapeutics Shares Plummet
November 07, 2022
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Monday.
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.